Matteo S Carlino

Matteo S Carlino

UNVERIFIED PROFILE

Are you Matteo S Carlino?   Register this Author

Register author
Matteo S Carlino

Matteo S Carlino

Publications by authors named "Matteo S Carlino"

Are you Matteo S Carlino?   Register this Author

83Publications

7989Reads

12Profile Views

Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events.

J Am Acad Dermatol 2020 Feb 21;82(2):311-316. Epub 2019 Jun 21.

Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical School, The University of Sydney, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.06.035DOI Listing
February 2020

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2019 10 28;381(16):1535-1546. Epub 2019 Sep 28.

From the Royal Marsden NHS Foundation Trust, London (J.L.), and the College of Medicine, Swansea University, Swansea (J.W.) - both in the United Kingdom; the Oncology Institute of Veneto IRCCS, Padua (V.C.-S.), the European Institute of Oncology, IRCCS, Milan (P.F.F.), Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples (P.A.A.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and the Center for Immuno-Oncology, Medical Oncology and Immunotherapy, University Hospital, Siena (M.M.) - all in Italy; the University of Colorado Cancer Center, Aurora (R.G.); Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille Hôpital Timone, Marseille (J.-J.G.), and Université de Paris, INSERM Unité 976, Assistance Publique-Hôpitaux de Paris Dermatology and Centres d'Investigation Clinique, Saint Louis Hospital, Paris (C.L.) - both in France; the Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); the University of Michigan, Ann Arbor (C.D.L.); Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Universitäts Spital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB (M.S.), and the Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Tasman Oncology Research, Southport, QLD (A.H.), the Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney, Sydney, NSW (M.S.C., G.V.L.), and the Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and the Peter MacCallum Cancer Centre, Melbourne, VIC (G.M.) - all in Australia; General University Hospital Gregorio Marañon and Centro de Investigación Biomédica en Red de Oncología, Madrid (I.M.-R.); the Netherlands Cancer Institute, Amsterdam (J.H.); the Leuven Cancer Institute, Department of General Medical Oncology, University Hospital Leuven, Leuven, Belgium (P.S.); University of California San Diego Health-La Jolla Moores Cancer Center, La Jolla (G.A.D.); the Department of Oncology, Odense University Hospital, Odense, Denmark (L.B.); Bristol-Myers Squibb, Princeton, NJ (J.I.R., A.B., A.M.); Dana-Farber Cancer Institute, Boston (F.S.H.); and the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1910836DOI Listing
October 2019

Oncogenic signaling in uveal melanoma.

Pigment Cell Melanoma Res 2018 11 23;31(6):661-672. Epub 2018 May 23.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12708DOI Listing
November 2018

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy.

Pigment Cell Melanoma Res 2018 07 10;31(4):509-515. Epub 2018 Jan 10.

Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12682
Publisher Site
http://dx.doi.org/10.1111/pcmr.12682DOI Listing
July 2018

Immune Checkpoint Inhibitor Toxicity.

Curr Oncol Rep 2018 07 31;20(9):72. Epub 2018 Jul 31.

Crown Princess Mary Cancer Centre, Westmead Hospital, Corner Hawkesbury & Darcy Roads, Westmead, NSW, 2145, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0718-6
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0718-6DOI Listing
July 2018

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Pigment Cell Melanoma Res 2018 05 7;31(3):404-410. Epub 2017 Dec 7.

Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12675DOI Listing
May 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma.

J Clin Oncol 2017 12 19;35(34):3792-3793. Epub 2017 Oct 19.

Matteo S. Carlino, Westmead and Blacktown Hospitals and University of Sydney, Sydney, New South Wales, Australia; and Shahneen Sandhu, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2055DOI Listing
December 2017

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

N Engl J Med 2017 10 11;377(14):1345-1356. Epub 2017 Sep 11.

From the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.D.W., M.A.P., M.K.C.); Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua (V.C.-S.), European Institute of Oncology, Milan (P.F.F.), Center for Immuno-Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), the Immunotherapy and Somatic Cell Therapy Unit, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (M.G.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; University of Colorado, Denver (R.G.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); Aix-Marseille University, Hôpital de la Timone, Marseille (J.-J.G.), and Assistance Publique-Hôpitaux de Paris, Dermatology and Centres d'Investigation Clinique, INSERM Unité 976, Hôpital Saint-Louis, Université Paris Diderot, Paris (C.L.) - both in France; Texas Oncology-Baylor Cancer Center, Dallas (C.L.C.); University of Michigan, Ann Arbor (C.D.L.); the College of Medicine, Swansea University, Swansea (J.W.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; the Department of Dermatology, University of Essen, Essen, and the German Cancer Consortium, Heidelberg - both in Germany (D.S.); Cross Cancer Institute, Edmonton, AB (M.S.), and Princess Margaret Cancer Centre, Toronto (D.H.) - both in Canada; Universitäts Spital, Zurich, Switzerland (R.D.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), Crown Princess Mary Cancer Centre, Melanoma Institute Australia, University of Sydney (M.S.C.), and Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals (G.V.L.), Sydney, and Peter MacCallum Cancer Centre (G.M.) and the Olivia Newton-John Cancer Research Institute, University of Melbourne (J.C.), Melbourne, VIC - all in Australia; Netherlands Cancer Institute, Amsterdam (J.H.); University Hospitals Leuven, KU Leuven, Leuven, Belgium (O.B.); General University Hospital Gregorio Marañón, Madrid (I.M.-R.); Northwestern University, Chicago (J.S.); Bristol-Myers Squibb, Princeton, NJ (D.W., L.R., R.B.); and the Dana-Farber Cancer Institute, Boston (F.S.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1709684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778PMC
October 2017

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

J Clin Oncol 2017 Mar 30;35(7):709-717. Epub 2016 Sep 30.

Jarushka Naidoo, Kaitlin M. Woo, Tunc Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Hira Rizvi, Xue Hou, Katherine Rodriguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center; Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan Rosenberg, Martin H. Voss, Charles M. Rudin, Jedd D. Wolchok, Michael A. Postow, and Matthew D. Hellmann, Weill Cornell Medical College, New York, NY; Jarushka Naidoo, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore, MD; Xuan Wang, Peking University Cancer Hospital and Institute, Beijing; Xue Hou, Sun Yat-sen University Cancer Center, Guangdong Province, People's Republic of China; Xuan Wang, Matteo S. Carlino, Benjamin Y. Kong, and Georgina V. Long, The University of Sydney; Alexander M. Menzies and Alexander D. Guminski, Royal North Shore and Mater Hospital; and Matteo S. Carlino and Benjamin Y. Kong, Westmead and Blacktown Hospitals, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559901PMC
March 2017

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.

Pigment Cell Melanoma Res 2017 01;30(1):68-71

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12557DOI Listing
January 2017

Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis.

Case Rep Med 2017 15;2017:5462929. Epub 2017 Jan 15.

Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/5462929DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5274679PMC
January 2017

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Br J Cancer 2016 Nov 6;115(11):1280-1284. Epub 2016 Oct 6.

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G. Pascale', Via Mariano Semmola, 80131 Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129828PMC
November 2016

Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies.

Melanoma Res 2016 08;26(4):413-6

Departments of aDermatology bTissue Pathology and Diagnostic Oncology cCrown Princess Mary Cancer Centre, Westmead Hospital dSydney Medical School, The University of Sydney eMelanoma Institute Australia, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/melanomaresearch/2016/08000/Bul
Web Search
http://dx.doi.org/10.1097/CMR.0000000000000260DOI Listing
August 2016

Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?

Clin Cancer Res 2016 Aug 23;22(16):3992-8. Epub 2016 Jun 23.

Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2944DOI Listing
August 2016

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.

Melanoma Res 2016 Apr;26(2):202-4

aCrown Princess Mary Cancer Centre bBlood and Marrow Transplant Service, Department of Haematology cDepartment of Clinical Immunology and Allergy, Westmead Hospital dFaculty of Medicine, The University of Sydney eMelanoma Institute Australia fFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000232DOI Listing
April 2016

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.

J Am Acad Dermatol 2016 Mar 12;74(3):455-61.e1. Epub 2016 Jan 12.

Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2015.10.029DOI Listing
March 2016

Biology and treatment of BRAF mutant metastatic melanoma.

Melanoma Manag 2016 Mar 12;3(1):33-45. Epub 2016 Feb 12.

Melanoma Institute Australia, North Sydney, NSW 2060, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.38DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097549PMC
March 2016

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

Crit Rev Oncol Hematol 2015 Dec 28;96(3):385-98. Epub 2015 Aug 28.

Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2015.08.021DOI Listing
December 2015

Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.

JAMA Dermatol 2015 Oct;151(10):1103-9

Department of Dermatology, Westmead Hospital, Sydney, Australia2University of Sydney Medical Faculty, Sydney Medical School, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jam
Publisher Site
http://dx.doi.org/10.1001/jamadermatol.2015.1745DOI Listing
October 2015

Immune checkpoint inhibitors in melanoma.

Melanoma Manag 2015 Aug 10;2(3):267-284. Epub 2015 Aug 10.

Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094677PMC
August 2015

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.

Mod Pathol 2015 Jul 3;28(7):884-94. Epub 2015 Apr 3.

1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia [3] Kolling Institute, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/modpathol201534
Publisher Site
http://dx.doi.org/10.1038/modpathol.2015.34DOI Listing
July 2015

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

N Engl J Med 2015 Jul 31;373(1):23-34. Epub 2015 May 31.

From the Department of Medical Oncology, Royal Marsden Hospital, London (J.L.), and South West Wales Cancer Institute, Singleton Hospital, Swansea (J.W.) - both in the United Kingdom; Melanoma Oncology Unit, Veneto Region Oncology Research Institute, Padua (V.C.-S.), Oncology of Melanoma Unit, European Institute of Oncology, Milan (P.F.F.), University Hospital of Siena, Siena (M.M.), and Istituto Nazionale Tumori Fondazione Pascale, Naples (P.A.A.) - all in Italy; Division of Medical Oncology, University of Colorado, Denver, Denver (R.G.); Aix-Marseille University, Hôpital de La Timone, Assitance Publique-Hôpitaux de Marseille, Marseille (J.J.G.), and Hôtel Dieu Place Alexis Ricordeau, Nantes (B.D.) - both in France; Baylor Charles A. Sammons Cancer Center, Dallas (C.L.C.); Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor (C.D.L.); Department of Dermatology, University of Essen, Essen, Germany (D.S.); University of Zürich Hospital, Zurich, Switzerland (R.D.); Cross Cancer Institute, Edmonton, AB, Canada (M. Smylie); Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland (P.R.); Tasman Oncology Research, Southport Gold Coast, QLD (A.H.), and Westmead and Blacktown Hospitals (M.S.C.) and Melanoma Institute Australia (M.S.C., G.V.L.), University of Sydney, and the Mater Hospital (G.V.L.), Sydney, and Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC (G.A.M.) - all in Australia; Division of Medical Oncology, the Netherlands Cancer Institute, Amsterdam (J.B.H.); Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid (I.M.-R.); Ludwig Center, Memorial Sloan Kettering Cancer Center (M.K.C., M.A.P., J.D.W.) and Weill Cornell Medical College (M.K.C., M.A.P., J.D.W.) - both in New York; Huntsman Cancer Institute, University of Utah, Salt Lake City (K.G.); Yale Cancer Center, Smilow Cancer Hospital of the Yale-New Haven Hospital, Yale University Sc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1504030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905PMC
July 2015

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

J Clin Oncol 2015 Apr 12;33(11):e52-6. Epub 2014 May 12.

Melanoma Institute Australia; The University of Sydney and Westmead Institute for Cancer Research, Sydney, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.5783DOI Listing
April 2015

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Clin Cancer Res 2015 Jan 4;21(1):98-105. Epub 2014 Nov 4.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia. Australian School of Advanced Medicine, Macquarie University, New South Wales, Australia. Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0759DOI Listing
January 2015

Resistance to c-Kit inhibitors in melanoma: insights for future therapies.

Oncoscience 2014 6;1(6):423-6. Epub 2014 Jun 6.

Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia ; Department of Medical Oncology, Westmead and Blacktown Hospitals, New South Wales, Australia ; Australian School of Advanced Medicine, Macquarie University, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284619PMC
http://dx.doi.org/10.18632/oncoscience.51DOI Listing
January 2015

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Nat Commun 2014 Dec 2;5:5694. Epub 2014 Dec 2.

1] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6694DOI Listing
December 2014

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Mol Oncol 2014 May 15;8(3):544-54. Epub 2014 Jan 15.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528644PMC
May 2014

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Clin Cancer Res 2014 Apr 24;20(7):1965-77. Epub 2014 Jan 24.

Authors' Affiliations: Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute; Departments of Medical Oncology and Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia; Disciplines of Pathology, Medicine, and Surgery, Sydney Medical School, The University of Sydney, Sydney; Departments of Melanoma and Surgical Oncology and Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3122DOI Listing
April 2014

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

Mol Cancer Ther 2013 Jul 3;12(7):1332-42. Epub 2013 May 3.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0011DOI Listing
July 2013

Treatment of melanoma brain metastases: a new paradigm.

Cancer J 2012 Mar-Apr;18(2):208-12

Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e31824b2890DOI Listing
July 2012

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Clin Cancer Res 2012 Jun 24;18(12):3242-9. Epub 2012 Apr 24.

Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-0052DOI Listing
June 2012